Intelligence · Clinical Pipeline
Theravance Biopharma Ireland Pipeline
All ClinicalTrials.gov programs at Theravance Biopharma Ireland — phase, modality, and trial IDs.
- Programs
- 57
Quick answer
Theravance Biopharma Ireland has 57 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
TD-8954
Theravance Biopharma Ireland Umited
Gastrointestinal Motility Disorder
1 trial -
TD-9855
Theravance Biopharma Ireland Umited
ADHD
1 trial -
TD-9855
Theravance Biopharma Ireland Umited
Drug Drug Interaction (DDI)
1 trial -
Telavancin
Theravance Biopharma Ireland Umited
Healthy
1 trial -
Velusetrag
Theravance Biopharma Ireland Umited
Alzheimer's Disease
1 trial -
[14C]-GSK961081 solution for IV infusion
Theravance Biopharma Ireland Umited
Pulmonary Disease, Chronic Obstructive
1 trial -
Revefenacin
Theravance Biopharma Ireland Umited
Chronic Obstructive Pulmonary Disease
1 trial -
Telavancin
Theravance Biopharma Ireland Umited
End-Stage Renal Disease
1 trial -
umeclidinium 62.5 µg and vilanterol 25 µg
Theravance Biopharma Ireland Umited
COPD (Chronic Obstructive Pulmonary Disease)
1 trial
Frequently asked questions
How many pipeline programs does Theravance Biopharma Ireland have?
57 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs